Associated tags: FDA, Coronary thrombosis, Pulmonary embolism, CE, VTE, Deep vein thrombosis, Medicine, Patient, Thrombosis, Inari, Pharmaceutical industry
Locations: WASHINGTON, PENNSYLVANIA, PHILADELPHIA, PE, DC, IRVINE, CA, US, UNITED STATES, INARI
IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.
Key Points:
- IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.
- A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at www.inarimedical.com.
Retrieved on:
Wednesday, April 17, 2024
IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024.
Key Points:
- IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its first quarter 2024 financial results on Tuesday, April 30, 2024.
- In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers.
- The live webinar may be accessed by visiting the Events Section of the Inari investor relations website or by registering here .
IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report.
Key Points:
- IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report.
- “We are proud to issue our third annual Ethos and Sustainability Report and highlight the ESG-focused initiatives we implemented during the past year,” said Drew Hykes, CEO of Inari Medical.
- “2023 was a great year for Inari, our patients, and our employees, as we focused on activities that embodied the Inari ethos.
- Our 2023 Ethos and Sustainability Report summarizes these activities and reflects the responsibility that we feel towards all stakeholders.”
Moses Austin,
Ohio State University,
Edwards Lifesciences,
Education,
Patient,
Global strategy,
SVP,
Coronary thrombosis,
Business development,
Radiology,
University,
Doctors Hospital,
Faculty,
Senior,
Abstract,
MD Anderson Cancer Center,
Hospital,
MitraClip,
Baptist Hospital,
Interventional radiology,
Health,
Global marketing IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
Key Points:
- IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
- Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
- Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
- We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.
Deep vein thrombosis,
Pulmonary embolism,
VTE,
Incidence,
Sequela,
CAVA,
Patient,
Post-thrombotic syndrome,
Research,
PTS,
DVT,
Randomized controlled trial,
Safety,
FACS,
American Venous Forum,
Data,
Pharmaceutical industry IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
Key Points:
- IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
- The interim results are the largest prospective, multi-center two-year dataset in deep vein thrombosis (DVT) since the ATTRACT trial and confirm the excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in real-world DVT patients.
- Patients had low incidence of independently adjudicated safety events related to rethrombosis, with only 5.0% and 8.4% at 30-days and 6 months, respectively.
- We remain committed to establishing the ClotTriever and FlowTriever systems as standard of care for deep vein thrombosis and pulmonary embolism (PE) patients.”
Retrieved on:
Wednesday, February 28, 2024
Acquisition,
VTE,
Randomized controlled trial,
Traction,
Marketing,
Average cost,
Growth,
GAAP,
Organization,
Patient,
RCT,
Net,
Research,
Bank Revenue was $132.1 million for the fourth quarter of 2023, up 22.6% compared to $107.8 million for the fourth quarter of 2022.
Key Points:
- Revenue was $132.1 million for the fourth quarter of 2023, up 22.6% compared to $107.8 million for the fourth quarter of 2022.
- Gross profit was $115.1 million for the fourth quarter of 2023, compared to $94.6 million for the fourth quarter of 2022.
- Gross margin was 87.1% for the fourth quarter of 2023, compared to 87.8% for the fourth quarter of 2022.
- Operating expenses for the fourth quarter of 2023 were $124.4 million, compared to $100.5 million for the fourth quarter of 2022.
Retrieved on:
Wednesday, February 14, 2024
IRVINE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024.
Key Points:
- IRVINE, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024.
- In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
- Interested parties may access the live call via telephone by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers.
- The live webinar may be accessed by visiting the Events Section of the Inari investor relations website or by registering here .
Coronary thrombosis,
Patient,
Traction,
Annual report,
RCT,
VTE,
FLAME,
Randomized controlled trial,
Isabella Tree,
Growth,
Pharmaceutical industry IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.
Key Points:
- IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.
- Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be at least $132.0 million, up approximately 22% year-over-year.
- Preliminary unaudited revenue for the full year 2023 is expected to be at least $493.5 million, up approximately 29% over the full year 2022.
- Further detail will be provided when Inari reports its financial results for the fourth quarter and full year 2023.
Retrieved on:
Wednesday, December 20, 2023
IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time.
Key Points:
- IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time.
- A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.
Retrieved on:
Monday, November 27, 2023
"PEERLESS II is challenging the most commonly administered first-line therapy for PE around the world,” said Dr. Matthai.
Key Points:
- "PEERLESS II is challenging the most commonly administered first-line therapy for PE around the world,” said Dr. Matthai.
- PEERLESS II is the largest study of its kind and will include up to 1,200 randomized patients at up to 100 global centers.
- Thank you to the PEERLESS II Steering Committee and clinical staff for helping us get the first patient enrolled."
- "Inari is actively enrolling three RCTs: PEERLESS, PEERLESS II and DEFIANCE, demonstrating our relentless commitment to guideline-changing research aimed at ultimately improving patient outcomes,” said Dr. Thomas Tu, Inari’s Chief Medical Officer.
